Remoxipride — a new potential antipsychotic compound

@article{Grind2004RemoxiprideA,
  title={Remoxipride — a new potential antipsychotic compound},
  author={Margaretha Grind and M. -I. Nilsson and Lars B. Nilsson and Gabriel Oxenstierna and G{\"o}ran Sedvall and A. Wahl{\'e}n},
  journal={Psychopharmacology},
  year={2004},
  volume={98},
  pages={304-309}
}
The tolerability and pharmacokinetics of remoxipride were studied in 18 healthy normal male volunteers. Increasing oral doses of 0.5–100 mg were given to eight male volunteers in one study (study I). In addition, an intravenous (IV) infusion of 20 mg remoxipride and a 20 mg oral dose were given in an open crossover study to ten males (study II). Remoxipride was well tolerated with respect to cardiovascular effects, clinical chemistry, body temperature and adverse effects in all subjects… 
Pharmacokinetics and effects on prolactin of remoxipride in patients with tardive dyskinesia
TLDR
In plots of the relationship between the concentration of remoxipride and the prolactin increase during a dosage interval, the curve on day 15 was positioned markedly to the right of that on day 1, indicating a decreased sensitivity to the prolACTin releasing action of remxipride following continuous treatment.
Neuroendocrine responses to single oral doses of remoxipride and sulpiride in healthy female and male volunteers
TLDR
No consistent effects on serum levels of LH, FSH, GH, oestradiol, progesterone, testosterone or cortisol could be detected after remoxipride and sulpiride compared to placebo, but effects on other hormones were also investigated.
Interaction study between remoxipride and biperiden
TLDR
Differences in prolactin Cmax and tmax following remoxipride versus concomitant (remoxipide + biperiden) treatment were not statistically significant, however, a slight but statistically significant increase in Prolactin AUC was observed after con comitant treatment.
Effects of remoxipride on measures of psychological performance in healthy volunteers
TLDR
The results indicate that remoxipride may have a slight depressant effect in the dose-range used, and is consistent with current theories on the role of dopamine in attention and arousal, and with the effects of other neuroleptics.
Effect of urinary pH on the plasma and urinary kinetics of remoxipride in man
TLDR
The urinary pH has a marked effect on the elimination kinetics of remoxipride, and after an overdose, treatment with ammonium chloride might be valuable in hastening elimination of remxipride from the body.
Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity.
TLDR
This pharmacological profile of amisulpride, characterized by a preferential blockade of effects involving presynaptic mechanisms and limbic structures, may explain the clinical efficacy of this drug against both negative and positive symptoms of schizophrenia and its low propensity to produce extrapyramidal side effects.
Effects of remoxipride, a dopamine D-2 antagonist antipsychotic, on sleep-waking patterns and EEG activity in rats and rabbits
TLDR
The results indicate that, unlike haloperidol, remoxipride has weak or no sedative effects, and provide support to the notion that D-2 receptors are not involved in the regulation of states of sleep and sedation.
In Vivo Validation of the Release Rate and Palatability of Remoxipride-Modified Release Suspension
TLDR
The taste-masked oral suspension is suitable for full-scale production, with good control of the encapsulation process and of the preparation of a suspension, and the release rates in vivo and in vitro were shown to be similar.
Biotransformation of Post-Clozapine Antipsychotics
TLDR
Although the promising benzisoxazole (iloperidone) and benzisothiazole (perospirone) antipsychotics share some metabolic routes with the structurally related available drugs, they too have pharmacologically relevant compound-specific pathways.
Regional distribution and in vivo binding of the atypical antipsychotic drug remoxipride. A biochemical and autoradiographic analysis in the rat brain
TLDR
These studies show that after i.v. injections,3H-remoxipride enters the brain primarily in unmetabolized form when given in doses that affect DA receptor mediated behaviours, that it distributes to most areas throughout the neuraxis and that it binds to D-2 receptors in different parts of the basal ganglia, neocortex, hippocampus and cerebellum.
...
1
2
...

References

SHOWING 1-10 OF 15 REFERENCES
Remoxipride — a new potential antipsychotic drug
TLDR
The drug induced a rapid and transient increase in plasma prolactin concentrations at both dose levels after single doses and a significant reduction in the Prolactin response was observed as compared to after the first dose.
Remoxipride, a new potential antipsychotic compound with selective antidopaminergic actions in the rat brain.
TLDR
Results indicate that remoxipride is a potent, selective D2 receptor blocking agent with a preferential action in mesolimbic and extrastriatal dopamine-containing neurons.
Effects of remoxipride and some related new substituted salicylamides on rat brain receptors.
A number of potential neuroleptic drugs of the substituted benzamide type have been compared with some reference neuroleptic drugs regarding their affinities for rat brain receptors using in vitro
Receptor-binding profiles of neuroleptics.
TLDR
It is suggested that D-1-receptor activation is responsible for dyskinesia, and that thioxanthenes - due to their D- 1 receptor blocking effect-induce less dyskine than other neuroleptics.
A method for estimating within-individual variability in clearance and in volume of distribution from standard bioavailability studies
TLDR
This model has given statistical evidence that clearance of theophylline is inherently more variable within individuals than volume of distribution, and use of the measurement AUC ·β rather than AUCas a more precise index of bioavailability is justified in studies where β is measured with reasonable precision.
Human dopamine receptor subtypes—in vitro binding analysis using3H-SCH 23390 and3H-raclopride
TLDR
The distribution of the dopamine receptor subtypes obtained in the present in vitro investigation is in agreement with data obtained with 11C-SCH 23390 and11C-raclopride in positron emission tomographic studies in human volunteers.
Estimation of absolute bioavailability assuming steady state apparent volume of distribution remains constant
TLDR
A noncompartmental method is described where, provided the reference dose is given intravenously, F can be estimated based on the assumption that Vss remains constant between doses, but is subject to error when the terminal loglinear slope of Cp vs. time better reflects the process of absorption rather than elimination.
Cardiovascular complications in young patients taking psychotropic drugs. A preliminary report.
Abstract Seven cases are presented in whom cardiac arrhythmias, myocardial failure, or conduction disturbances or significant electrocardiographic changes occurred during prolonged administration of
Drugs used in the treatment of psychosis. In: Goodman-Gilman A, Goodmann LS, Rall TW, Murad F (eds) The pharmacological basis of therapeutics
  • 7th edn. Macmillan,
  • 1985
...
1
2
...